New York-Adding high-dose vitamin D to docetaxel (Taxotere) in regimens for androgen-independent prostate cancer patients doubles the effectiveness of docetaxel as a single agent, according to results of a nonrandomized study from Oregon Health Sciences University, Portland.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.